CKM Population Planner for Payers and Health Systems
A dashboard for health systems to see how many patients have combined heart, kidney, and metabolic issues.
A dashboard that sizes a health plan's or hospital system's cardiovascular-kidney-metabolic (CKM) patient population against the American Heart Association's first-ever CKM statistics chapter, so leaders can build a defensible business case for integrated CKM care programs.
Concept
The 2026 AHA Statistics Update adds a brand-new chapter on cardiovascular-kidney-metabolic (CKM) syndrome — the overlapping cluster of obesity, diabetes, chronic kidney disease, and cardiovascular disease. That chapter gives payers and health systems their first consolidated national reference numbers for this population, but it arrives as a long, researcher-oriented report. The CKM Population Planner turns it into a planning instrument. A client connects a one-time aggregated claims/EHR extract (counts of members with diabetes, CKD stages, heart failure, and obesity codes); the tool applies CKM staging definitions, compares the client's CKM prevalence and cost profile against the national benchmarks in the 2026 Update, and produces (1) a quarterly-refreshed planning dashboard and (2) a one-time CKM program business case — sized population, projected avoidable cost, and the specific care-model investments (integrated nephro-cardio clinics, GLP-1 coverage policy, remote blood-pressure monitoring) that the numbers justify. The single wedge: converting the new CKM statistics into fundable program business cases for the people who approve budgets.
Why now
The 2026 Update is the first edition of the AHA's annual statistics report with a dedicated CKM syndrome chapter [0], so national reference figures for this exact population now exist and will be refreshed every year. The need is documented on both sides: the GBD 2023 analysis shows CKD is common and ranks among the leading causes of mortality and morbidity across 204 countries and territories [1], and U.S. multimorbidity research shows chronic conditions cluster in patterns that single-disease programs fail to capture [2] — precisely the population CKM staging defines. Today, payers size these programs with ad hoc internal estimates; a benchmark anchored to the AHA's own numbers makes the business case defensible to boards and regulators.
Written by GLM · 8 Oct 2026
AI assessment
A high-utility B2B planning tool that leverages a timely, authoritative new benchmark to help healthcare executives justify the budget for integrated CKM care models.
- Evidence strength 5/5
- The idea directly maps to the 2026 AHA Statistics Update's new CKM chapter, utilizing a specific, newly created national reference for a known clinical cluster.
- Market pull 4/5
- Payers and value-based care providers have high urgency to reduce costs associated with multimorbidity, and 'defensible business cases' are the primary currency for budget approval.
- Novelty & moat 4/5
- While other ideas focus on clinical flags or coaching, this is a strategic financial planning tool; it fills a gap by moving from individual patient risk to population-level financial justification.
- Feasibility 5/5
- The MVP is a data-processing pipeline and dashboard that applies existing AHA definitions to client claims data, requiring no new clinical trials or complex hardware.
- Wedge clarity 5/5
- The wedge is exceptionally sharp: converting a specific new research report into a fundable business case for budget holders.
- Simplicity / focus 5/5
- The product is a single, focused instrument (Population Planner) rather than an over-scoped platform.
Scored by Gemma 4 · 8 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Elevance Healthcompany
One of the largest U.S. payers, with medical-cost trend driven by cardiometabolic and kidney disease; the planner gives its population-health and actuarial teams AHA-anchored numbers to size CKM programs and set GLP-1 and kidney-care benefit policy.
- Oak Street Healthcompany
Value-based Medicare primary care built around cardiovascular risk; CKM population sizing directly supports its risk contracts and decisions on where to deploy integrated kidney-cardiovascular care.
- Geisingercompany
Integrated health system with established kidney and cardiovascular service lines; the planner's business-case output justifies standing up a combined CKM clinic and measuring it against national benchmarks.
- Intermountain Healthcompany
Large integrated system with mature population-health infrastructure; uses the planner to prioritize CKM care-model investment across its regions.
- American Heart Associationorganization
Publisher of the statistics and sponsor of a national cardiovascular-kidney-metabolic health initiative; a planning tool built on its new chapter extends the reach of its data from researchers to the payer and system leaders who fund care.
Research it builds on
- Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023Patrick Barry Mark, Lauryn K Stafford, Morgan Erika Grams et al. · 2025 · 397 citationsAll ideas from this paper →
- 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart AssociationLatha P Palaniappan, Norrina B. Allen, Zaid Almarzooq et al. · 2026 · 223 citationsAll ideas from this paper →
- Multimorbidity Patterns in the United States: Implications for Research and Clinical PracticeRichard A. Goodman, Shari M. Ling, Peter A. Briss et al. · 2015 · 78 citationsAll ideas from this paper →